Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 80 Women only

Online adaptive radiotherapy for cervical cancer treatment

Official title: Online Adaptive Radiotherapy (oART) in Radical Radiotherapy for Cervical Cancer - A Multi-center Randomized Controlled Study

Run by Peking Union Medical College Hospital · NCT06562166 · Data updated 2026-11-12

This study tests if a new online adaptive radiotherapy can help women with cervical cancer get better results and experience fewer side effects compared to standard treatment.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 80 Years
SexWomen only
Enrollment124 (estimated)
SponsorPeking Union Medical College Hospital
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Beijing)
StatusRecruiting
StartedSeptember 5, 2024
Main results expectedAugust 1, 2027
Study endsDecember 1, 2028
Registry record updatedJanuary 8, 2026
Trial IDNCT06562166 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-70 with pathologically confirmed cervical squamous carcinoma at specific FIGO stages who are eligible for radical pelvic radiotherapy.

Probably not a fit

Patients with non-squamous types of cervical cancer or those not meeting the eligibility criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the clinical efficacy and safety of online adaptive radiotherapy in patients with cervical cancer undergoing radical radiotherapy. It compares this approach with traditional image-guided radiotherapy to assess potential benefits in reducing treatment toxicity and enhancing local control of the cancer. The trial includes patients aged 18-70 with confirmed cervical squamous carcinoma and specific FIGO stages, who will receive concurrent chemotherapy. The study aims to provide insights into the effectiveness of adaptive radiotherapy in improving patient outcomes.

Why it matters

Potential benefit: If successful, this approach could lead to reduced treatment side effects and improved cancer control for cervical cancer patients.

How similar studies have gone: Previous studies have shown promise in adaptive radiotherapy approaches, suggesting potential benefits, though this specific application may be novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 18-80 years old;
2. Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma;
3. 2018 FIGO Stage Ib3, II, IIIB and IIIC1
4. Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses)
5. ECOG score 0-2
6. Life expectancy greater than 6 months
7. Ability to remain lying down for more than 30 minutes
8. Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form
9. Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal
10. Must complete baseline assessments and investigations required before treatment before enrolment
11. be eligible for regular follow-up

Exclusion Criteria:

1. Have received radiotherapy or chemotherapy in the past
2. Have undergone radical surgery for cervical cancer
3. Have a previous history of malignant tumor
4. Pregnant or lactating women
5. Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.

Where it's running

  • Peking union medical college hospital
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.